Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update

er Conference. The

final efficacy results confirmed previously announced interim

results showing a survival benefit in patients with recurrent SCLC

who failed prior platinum-containing first-line chemotherapy or who

progressed within six months of first-line therapy. The median

overall survival in the picoplatin Phase 2 trial was 27 weeks for

refractory and resistant small cell lung cancer patients, a

population for which there is no approved therapy in the US. The

Pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse)

trial of intravenous picoplatin in SCLC is ongoing and compares

picoplatin with best supportive care to best supportive care alone.

The published median overall survival for best supportive care is 13

weeks for the platinum refractory and resistant patient group. Our

registrational trial is currently being conducted under a Special

Protocol Assessment from the U.S. Food and Drug Administration and

is evaluating overall survival as the primary endpoint. Top-line

Phase 3 data is targeted for mid-2009.

* Colorectal Cancer: In January, we presented preliminary safety data

from our 50-patient Phase 1 dose-escalation study of picoplatin in

patients with metastatic colorectal cancer at the ASCO

Gastrointestinal Cancers Symposium. Picoplatin was shown to have

manageable toxicity in combination with 5-fluorouracil and

leucovorin. Picoplatin did not cause severe neurotoxicity (Grade 3

or higher), as is commonly seen in metastatic CRC patients treated

with oxaliplatin as part of the FOLFOX regimen. Current National

Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in

Oncology for colon cancer encourage the discontinuation of FOLFO

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
(Date:10/7/2015)... 7, 2015 Boston Scientific (NYSE: ... the Boston Scientific Connected Patient Challenge , an ... use of remote patient monitoring to enhance patient care.  ... can submit their ideas and collaborate on solutions through ... Cambridge, MA where they ...
(Date:10/7/2015)... Oct. 7, 2015  ChromaDex Corp. (OTCQX: CDXC), ... ingredients that creates science-based solutions for dietary supplement, ... pharmaceutical products, today announced that the October 1 ... Founder, is now available for on-demand viewing at ...   --> LINK: ...
(Date:10/7/2015)...  October is National Liver Awareness Month and in ... a portion of its October profits to support the ... "TRL is ... ways; whether it is by providing the highest quality ... in different disease and investigation areas, or directly donating ...
(Date:10/7/2015)... ... October 07, 2015 , ... Park Systems , world-leader ... to provide a comprehensive overview of the innovations in smart coatings using nanoparticle ... . This webinar will be given by Professor Roberto Advincula, professor with the ...
Breaking Biology Technology:
... a 360-degree look at the "state of play" on ... CQ Forum will include a panel discussion with industry ... complex structures of biologics products vs. traditional pharmaceuticals. Are ... save money for consumers? What is the right length ...
... - AEterna Zentaris Inc. (NASDAQ: AEZS ; ... therapy and oncology, today reported that patient follow-up in ... 3 program in benign prostatic hyperplasia (BPH) with its ... completed at the end of this week. Therefore, data ...
... ... of the Year presented by Frost & Sullivan , ... Charlottesville, VA, New York, NY and Paris, France (PRWEB) June 15, ... tools, announces that it has received the prestigious 2009 Global Pharmaceutical CRM Growth Strategy Leadership ...
Cached Biology Technology:
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
(Date:9/26/2015)... , Sept. 26th, 2015  Results of ... will be unveiled today at the Stanford Medicine ... Engagement Using iPad Dashboards, Connected Health Devices and ... of Pharmacy 3.0, will explain how senior patients ... data to their pharmacist via the TactioRPM remote ...
(Date:9/24/2015)... , September 24, 2015 ... september 2015 Kerv ( ... finanstjänster, lanserar idag världens första kontaktlösa betalningsring ... in 77 000 GBP för massproduktion via ... ) , Kerv-bärare kan ...
Breaking Biology News(10 mins):
... 15,000 years ago and it is widely assumed that ... with humans stems from changes during the domestication process. ... the animals have not received much attention. The point ... two members of the University of Veterinary Medicine, Vienna ...
... to how the pathogen responsible for the Irish potato ... Researchers at Oxford University and The Sainsbury Laboratory (Norwich, ... infestans , a pathogen that continues to blight potatoes ... The study, published today in the journal Science ...
... , TORONTO, Feb. 1, 2014 Researchers at St. Michael,s ... the sugar most commonly blamed for obesity, with glucose in ... edition of Current Opinion in Lipidology , show that ... not cause any more harm than glucose. "Despite concerns ...
Cached Biology News:
... a silica based spin filter membrane to isolate ... DNA band is cut from an agarose gel ... The gel slice is melted irreversibly in a ... bound to the silica spin filter membrane and ...
... incorporation of Br-dUTP results in a stronger ... a fluorescein-labeled anti-BrdU antibody. Propidium iodide/RNase ... to counterstain the total DNA. Features and ... improved detection than found by using biotin- ...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Biology Products: